Characteristics of patients who underwent allogeneic transplantation for MM between 1989 and 2005 by year of transplantation, reported to CIBMTR
| . | 1989-1994 . | 1995-2000 . | 2001-2005 . | P . |
|---|---|---|---|---|
| Patient-related variables | ||||
| No. of patients | 343 | 376 | 488 | |
| No. of centers | 84 | 102 | 121 | |
| Age at transplantation, y | < .001 | |||
| Median (range) | 44 (24-59) | 47 (22-66) | 51 (24-70) | < .001 |
| < 40 y, n (%) | 99 (29) | 67 (17) | 52 (11) | |
| 40-49 y, n (%) | 203 (59) | 174 (46) | 177 (36) | |
| 50-59 y, n (%) | 41 (12) | 120 (32) | 196 (40) | |
| 60-69 y, n (%) | 0 | 15 (4) | 63 (13) | |
| Male sex, n (%) | 194 (57) | 243 (65) | 295 (60) | .086 |
| Karnofsky score < 90% before transplantation, n (%) | 128 (37) | 148 (39) | 165 (34) | .229 |
| Disease-related variables | ||||
| Immunologic subtype | .019† | |||
| IgG, n (%) | 13 (4) | 207 (55) | 230 (47) | |
| IgA, n (%) | 8 (2) | 57 (15) | 80 (16) | |
| IgD, n (%) | 0 | 3 (< 1) | 6 (1) | |
| Light chain, n (%) | 14 (4) | 61 (16) | 91 (19) | |
| Nonsecretory, n (%) | 9 (3) | 20 (5) | 26 (5) | |
| Not specified or missing, n (%) | 299 (87) | 28 (7) | 55 (11) | |
| Durie-Salmon stage at diagnosis | .11† | |||
| Stage I, n (%) | 3 (< 1) | 37 (10) | 40 (8) | |
| Stage II, n (%) | 9 (3) | 109 (29) | 111 (23) | |
| Stage III, n (%) | 21 (6) | 199 (53) | 288 (59) | |
| Missing, n (%) | 310 (90) | 31 (8) | 49 (10) | |
| Sensitivity to chemotherapy before transplantation | .011† | |||
| Sensitive, n | 20 (6) | 219 (58) | 314 (64) | |
| Resistant, n | 15 (4) | 107 (28) | 140 (29) | |
| Missing/not applicable, n | 308 (90) | 50 (13) | 34 (7) | |
| Cytogenetics | * | |||
| Abnormal | 2 | 23 | 33 | |
| Normal | 3 | 44 | 106 | |
| Not performed/reported | 338 | 309 | 349 | |
| Total | 343 | 376 | 488 | |
| Transplantation-related variables | ||||
| Time from diagnosis to transplantation, mo | ||||
| Median (range) | 15 (2-169) | 13 (1-233) | 15 (2-171) | .025 |
| < 12 mo, n (%) | 127 (37) | 183 (49) | 202 (41) | |
| 12-18 mo, n (%) | 64 (19) | 50 (13) | 77 (16) | |
| ≥ 18 mo, n (%) | 152 (44) | 143 (38) | 209 (43) | |
| No. of lines of chemotherapy, excluding priming | ||||
| 1, n (%) | 9 (3) | 74 (20) | 134 (28) | < .001† |
| 2, n (%) | 5 (1) | 70 (19) | 67 (14) | |
| Missing, n (%) | 329 (96) | 232 (62) | 287 (59) | |
| Prior autologous transplantation, n (%) | 9 (3) | 86 (23) | 313 (64) | < .001 |
| Time from auto-HCT to allo-HCT, mo | ||||
| Median (range) | 11 (3-31) | 16 (2-77) | 6 (1-89) | .001 |
| < 6 mo, n (%) | 2 (< 1) | 20 (5) | 154 (32) | |
| 6-12 mo, n (%) | 3 (< 1) | 13 (3) | 38 (8) | |
| 12-24 mo, n (%) | 2 (< 1) | 21 (6) | 45 (9) | |
| > 24 mo, n (%) | 336 (98) | 322 (86) | 251 (51) |
| . | 1989-1994 . | 1995-2000 . | 2001-2005 . | P . |
|---|---|---|---|---|
| Patient-related variables | ||||
| No. of patients | 343 | 376 | 488 | |
| No. of centers | 84 | 102 | 121 | |
| Age at transplantation, y | < .001 | |||
| Median (range) | 44 (24-59) | 47 (22-66) | 51 (24-70) | < .001 |
| < 40 y, n (%) | 99 (29) | 67 (17) | 52 (11) | |
| 40-49 y, n (%) | 203 (59) | 174 (46) | 177 (36) | |
| 50-59 y, n (%) | 41 (12) | 120 (32) | 196 (40) | |
| 60-69 y, n (%) | 0 | 15 (4) | 63 (13) | |
| Male sex, n (%) | 194 (57) | 243 (65) | 295 (60) | .086 |
| Karnofsky score < 90% before transplantation, n (%) | 128 (37) | 148 (39) | 165 (34) | .229 |
| Disease-related variables | ||||
| Immunologic subtype | .019† | |||
| IgG, n (%) | 13 (4) | 207 (55) | 230 (47) | |
| IgA, n (%) | 8 (2) | 57 (15) | 80 (16) | |
| IgD, n (%) | 0 | 3 (< 1) | 6 (1) | |
| Light chain, n (%) | 14 (4) | 61 (16) | 91 (19) | |
| Nonsecretory, n (%) | 9 (3) | 20 (5) | 26 (5) | |
| Not specified or missing, n (%) | 299 (87) | 28 (7) | 55 (11) | |
| Durie-Salmon stage at diagnosis | .11† | |||
| Stage I, n (%) | 3 (< 1) | 37 (10) | 40 (8) | |
| Stage II, n (%) | 9 (3) | 109 (29) | 111 (23) | |
| Stage III, n (%) | 21 (6) | 199 (53) | 288 (59) | |
| Missing, n (%) | 310 (90) | 31 (8) | 49 (10) | |
| Sensitivity to chemotherapy before transplantation | .011† | |||
| Sensitive, n | 20 (6) | 219 (58) | 314 (64) | |
| Resistant, n | 15 (4) | 107 (28) | 140 (29) | |
| Missing/not applicable, n | 308 (90) | 50 (13) | 34 (7) | |
| Cytogenetics | * | |||
| Abnormal | 2 | 23 | 33 | |
| Normal | 3 | 44 | 106 | |
| Not performed/reported | 338 | 309 | 349 | |
| Total | 343 | 376 | 488 | |
| Transplantation-related variables | ||||
| Time from diagnosis to transplantation, mo | ||||
| Median (range) | 15 (2-169) | 13 (1-233) | 15 (2-171) | .025 |
| < 12 mo, n (%) | 127 (37) | 183 (49) | 202 (41) | |
| 12-18 mo, n (%) | 64 (19) | 50 (13) | 77 (16) | |
| ≥ 18 mo, n (%) | 152 (44) | 143 (38) | 209 (43) | |
| No. of lines of chemotherapy, excluding priming | ||||
| 1, n (%) | 9 (3) | 74 (20) | 134 (28) | < .001† |
| 2, n (%) | 5 (1) | 70 (19) | 67 (14) | |
| Missing, n (%) | 329 (96) | 232 (62) | 287 (59) | |
| Prior autologous transplantation, n (%) | 9 (3) | 86 (23) | 313 (64) | < .001 |
| Time from auto-HCT to allo-HCT, mo | ||||
| Median (range) | 11 (3-31) | 16 (2-77) | 6 (1-89) | .001 |
| < 6 mo, n (%) | 2 (< 1) | 20 (5) | 154 (32) | |
| 6-12 mo, n (%) | 3 (< 1) | 13 (3) | 38 (8) | |
| 12-24 mo, n (%) | 2 (< 1) | 21 (6) | 45 (9) | |
| > 24 mo, n (%) | 336 (98) | 322 (86) | 251 (51) |